Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Indices rise and fall as growth, inflation, and risk appetite shift; news and expectations reshape valuation baselines and asset flows.
21,301 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
AST SpaceMobile has surged, leaving investors asking whether spacemobile buy, sell, hold makes sense now. This articl...
Tesla faces a fresh wave of headwinds as policy, competition, and software bets collide with a fragile growth narrati...
QVC is leaning into TikTok's live shopping fever as traditional TV fades. The move aims to spark a new growth engine ...
Could investing $10,000 walmart really boost your wealth? This guide dives into Walmart's growth story, realistic ret...
AI is advancing beyond chips. NVIDIA's networking revenue just signals a broader shift to end-to-end AI infrastructur...
The idea of a sweeping Sell America trade captured headlines for years. This article breaks down what happened, why i...
A $295 million crypto hack shook a Solana-based exchange. This article explains how solana exchange drift plans to co...
A clear read of SERA’s Q1 2026 numbers and management commentary can shift an investor’s view of 2026. This guide bre...
A new collaboration blends AI agents, stablecoins, and cloud services. Learn how amazon teams with coinbase and Strip...
Investors are watching Crinetics' Q1 2026 results for clues on milestones, cash runway, and partnerships. This guide ...
When the AI spotlight faded in April, some top names cooled off just enough to become bargains. This piece breaks dow...